Sciclone Pharmaceuticals, Inc. (SCLN) Misses Q4 EPS by 8c, Guides FY13

Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q4 EPS of $0.04, $0.08 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $35.3 million.

Sciclone Pharmaceuticals, Inc. sees FY2013 EPS of $0.66-0.72, versus the consensus of $0.65. Sees FY revs of $150 to $155 million vs $153.07 expected.

For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• Leadership change and unchanged forecast send Avient stock tumbling 8%
• Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'